0C8:F:F-Catalent Inc (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 54.74

Change

+0.31 (+0.57)%

Market Cap

USD 10.01B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey. Address: 14 Schoolhouse Road, Somerset, NJ, United States, 08873

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
MRK:F Merck & Company Inc

N/A

USD 69.80B
MRKC:F MERCK KGAA NAM.SP.ADR

-0.20 (-0.65%)

USD 66.96B
H6D0:F Haleon PLC

-0.03 (-0.71%)

USD 43.69B
H6D:F Haleon PLC

-0.05 (-0.54%)

USD 42.63B
TKDA:F Takeda Pharmaceutical Company ..

-0.10 (-0.78%)

USD 41.72B
TEV:F Teva Pharmaceutical Industries..

+0.20 (+1.28%)

USD 17.73B
3KY:F HANSOH PHARMAC. HD-00001

+0.08 (+3.31%)

USD 13.16B
RDDA:F Dr. Reddy's Laboratories Limit..

N/A

USD 12.13B
SH0:F Shionogi & Co. Ltd

N/A

USD 11.21B
NB3:F Neurocrine Biosciences Inc

-2.10 (-2.04%)

USD 10.43B

ETFs Containing 0C8:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.35% 76% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.35% 66% D+ 76% C+
Trailing 12 Months  
Capital Gain 35.83% 79% B- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.83% 70% C- 70% C-
Trailing 5 Years  
Capital Gain 25.55% 69% C- 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.55% 51% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 7.38% N/A N/A 64% D
Dividend Return 7.38% N/A N/A 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 46.93% N/A N/A 22% F
Risk Adjusted Return 15.72% N/A N/A 47% F
Market Capitalization 10.01B 95% A 85% B

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector